PDTs are the future of DTx. Given the convergence of non-prescription or D2C DTx into remote patient monitoring and telehealth platforms, this is now creating a beeline for DTx to be what their name suggests - therapies that are delivered digitally. Happening at the back of the release of the HealthXL- Exits & Outcomes PDT Report, this meeting will explore some of the key findings in the report, including questions on the rigor of clinical and economic evidence required of PDTs, regulatory requirements of PDTs, and means (or lack thereof) to prescribe these therapies to the relevant candidates.